Lack of interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan in healthy volunteers

Clinical Drug Investigation

Volumn 14, Issue 3, 1997, Pages 217-220

  Veronese, L ^a   Gillotin, C ^a   Marion Gallois, R ^a   Weatherley, B C ^b   Thebault, J J ^c   Guillaume, M ^c   Peck, R W ^b  

^a GlaxoWellcome   (France)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Aster   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; DIHYDROERGOTAMINE; ZOLMITRIPTAN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0030881262     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714030-00009     Document Type: Article

References (9)

1. Ferrai MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996; 36 Suppl. 2: 4-7
2. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in the cat is inhibited by the novel serotonin receptor agonist 311C90. Headache 1994; 34: 394-9
3. Seaber E, On N, Phillips S, et al. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996; 42: 141-7
4. Dixon R, Gillotin CG, Gibbens M, et al. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 1997; 43: 273-81
5. Mellander S, Nordenfelt I. Peripheral and central circulatory effects of dihydroergotamine. Postgrad Med J 1976; 52 Suppl. 1: 17-20
6. Koch GG. The use of non-parametric methods in the statistical analysis of the two period crossover design. Biometrics 1972; 82: 577-84
7. 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose range finding study. Neurology 1996; 46: 522-6
8. Seaher E, On N, Dixon R, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan. Br J Clin Pharm 1997; 43: 571-87
9. Dollery C, editor. Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991: D136-40